Life Sciences weekly highlights—18 March 2021

Published on: 18 March 2021

Published by: LexisPSL

Life Sciences weekly highlights—18 March 2021
In this issue:
Brexit
Updated MHRA guidance—two-year notice period to amend recognition of EU batch testing
Amending Regulation on derogation from wholesalers’ obligation to decommission unique identifier of products exported to UK published in Official Journal
Coronavirus (COVID-19)
Gove outlines plans to review coronavirus (COVID-19) status certificates
Coronavirus (COVID-19)—European Commission proposes a Digital Green Certificate
MHRA responds to Ireland’s suspension of AstraZeneca coronavirus (COVID-19) vaccine
MHRA response to AstraZeneca coronavirus (COVID-19) vaccine suspension

More...

EMA investigation into coronavirus (COVID-19) AstraZeneca vaccination update
Commission publishes guidance on standards for coronavirus (COVID-19) rapid tests
EMA publishes guidance on coronavirus (COVID-19) medicine labelling
European Parliament expresses concerns about coronavirus (COVID-19) variants
Research and development
EMA Management Board publishes highlights from March 2021 meeting
Council of the EU adopts first reading position on €95.5bn research programme
Manufacture, marketing and sale
MDCG issued a new Q&A document on medical devices
Intellectual property
Coronavirus (COVID-19)—EPO publish Patent Index 2020
Disputes and regulatory enforcement
MWG launched to investigate effect of mergers on pharmaceuticals industry
Daily and weekly news alerts
New and updated content
Updated Practice Notes
Dates for your diary
Trackers
Useful information

Article summary

This week's edition of Life Sciences weekly highlights includes news that the MHRA has introduced a two-year notice period for any changes to the continued recognition of EU batch testing, updates on the UK and EU plans to introduce coronavirus (COVID-19) vaccine certificates, the revised go-live date for the EU IT systems required by Regulation (EU) 536/2014, the Clinical Trials Regulation, to 31 January 2022, and the Medical Device Co-ordination Group’s Q&A guidance on custom-made medical devices. Sign in or take a trial to read the full analysis.